Clinical toxicological aspects of fluoroquinolones

被引:143
作者
Stahlmann, R [1 ]
机构
[1] Free Univ Berlin, Inst Clin Pharmacol & Toxicol, D-14195 Berlin, Germany
关键词
fluoroquinolones; toxicity; antimicrobial therapy;
D O I
10.1016/S0378-4274(01)00509-4
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Reactions of the gastrointestinal tract and the central nervous system are the most often observed adverse effects during therapy with fluoroquinolones. Pathogenesis of the neurotoxic effects of fluoroquinolones could be related to the activation of the NMDA receptor. Animal experiments as well as clinical experience show that the cardiotoxic potentials of sparfloxacin and grepafloxacin are higher than those of the other fluoroquinolones: they cause QT prolongation at rather low doses thus increasing the risk for severe arrhythmia (torsades de pointes). Phototoxicity has been described for all quinolones, but derivatives with a halogen atom at position 8 show the highest potential for such reactions (e.g. clinafloxacin). Chondrotoxicity of quinolones can affect the articular cartilage and the epiphyseal growth plate in immature animals; the use of these drugs in pediatrics should be restricted to carefully selected indications (such as the use of ciprofloxacin in cystic fibrosis). Tendinitis and tendon ruptures can also be induced by quinolones. Overall, quinolones are as well tolerated as most other anti-microbial agents. However, their specific toxic potentials have to be considered when they are chosen for treatment of bacterial infections. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:269 / 277
页数:9
相关论文
共 32 条
[1]   STRUCTURE-EPILEPTOGENICITY RELATIONSHIP OF QUINOLONES WITH SPECIAL REFERENCE TO THEIR INTERACTION WITH GAMMA-AMINOBUTYRIC ACID RECEPTOR-SITES [J].
AKAHANE, K ;
SEKIGUCHI, M ;
UNE, T ;
OSADA, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (10) :1704-1708
[2]  
Anderson ME, 2001, J PHARMACOL EXP THER, V296, P806
[3]  
BAILEY RR, 1983, NEW ZEAL MED J, V96, P590
[4]   ADVERSE REACTIONS IN A DOSE-RANGING STUDY WITH A NEW LONG-ACTING FLUOROQUINOLONE, FLEROXACIN [J].
BOWIE, WR ;
WILLETTS, V ;
JEWESSON, PJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (10) :1778-1782
[5]  
BREEN J, 1999, J RESP DIS S, V20, pS70
[6]   Ciprofloxacin in pediatrics: Worldwide clinical experience based on compassionate use - Safety report [J].
Hampel, B ;
Hullmann, R ;
Schmidt, H .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (01) :127-129
[7]   Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG [J].
Kang, JS ;
Wang, L ;
Chen, XL ;
Triggle, DJ ;
Rampe, D .
MOLECULAR PHARMACOLOGY, 2001, 59 (01) :122-126
[8]  
KAPPEL E, 2001, CLIN MICROBIOL INFEC, V7, P160
[10]   HISTOLOGICAL EXAMINATION ON ACHILLES-TENDON LESIONS INDUCED BY QUINOLONE ANTIBACTERIAL AGENTS IN JUVENILE RATS [J].
KATO, M ;
TAKADA, S ;
KASHIDA, Y ;
NOMURA, M .
TOXICOLOGIC PATHOLOGY, 1995, 23 (03) :385-392